Overexpression and Characterization of a Carboxypeptidase from the Hyperthermophilic Archaeon Thermococcus Sp

Total Page:16

File Type:pdf, Size:1020Kb

Overexpression and Characterization of a Carboxypeptidase from the Hyperthermophilic Archaeon Thermococcus Sp Biosci. Biotechnol. Biochem., 70 (5), 1140–1147, 2006 Overexpression and Characterization of a Carboxypeptidase from the Hyperthermophilic Archaeon Thermococcus sp. NA1 Hyun Sook LEE, Yun Jae KIM, Seung Seob BAE, Jeong Ho JEON, y Jae Kyu LIM, Sung Gyun KANG, and Jung-Hyun LEE Korea Ocean Research & Development Institute, Ansan P.O. Box 29, Seoul 425-600, Korea Received September 14, 2005; Accepted January 11, 2006 Genomic analysis of a hyperthermophilic archaeon, peptidase Taq),2) T. thermophilus,3) and the hyperther- Thermococcus sp. NA1, revealed the presence of an mophilic archaeon Pyrococcus furiosus4) have been 1,497 bp open reading frame, encoding a protein of 499 purified and characterized so far. Thermostable carboxy- amino acids. The deduced amino acid sequence was peptidase 1 is known to be very thermostable, with a similar to thermostable carboxypeptidase 1 from Pyro- temperature optimum of 80–100 C.2,4) High optimum coccus furiosus, a member of peptidase family M32. Five temperatures for activity have been reported for other motifs, including the HEXXH motif with two histidines carboxypeptidases purified from the bacterium Ther- coordinated with the active site metal, were conserved. moactinomyces vulgaris5) and the archaeon Sulfolobus The carboxypeptidase gene was cloned and overex- solfataricus,6) with temperature optima of 60 and 85 C pressed in Escherichia coli. Molecular masses assessed respectively. by SDS–PAGE and gel filtration were 61 kDa and Thermostable carboxypeptidase 1 exhibits broad sub- 125 kDa respectively, which points to a dimeric struc- strate specificities. For instance, P. furiosus CP releases ture for the recombinant enzyme, designated TNA1 CP. basic, aromatic, neutral, and polar amino acids from the The enzyme showed optimum activity toward Z-Ala- C-terminus while it is unable to digest peptides with C- À1 À1 4) Arg at pH 6.5 and 70–80 C(kcat=Km ¼ 8:3 mM s ). terminal Gly, Pro, or acidic residues (Asp and Glu). In In comparison with that of P. furiosus CP (kcat=Km ¼ the case of carboxypeptidase Taq, it cleaves C-terminal 667 mMÀ1 sÀ1), TNA1 CP exhibited 80-fold lower cata- neutral, basic, and acidic amino acids most readily, with lytic efficiency. The enzyme showed broad substrate the exception of Pro and hydrolyses amino acids with specificity with a preference for basic, aliphatic, and long side chains.2) aromatic C-terminal amino acids. This broad specificity The biological role of microbial metallocarboxypep- was confirmed by C-terminal ladder sequencing of tidases has not been established, while mammalian porcine N-acetyl-renin substrate by TNA1 CP. metallocarboxypeptidases play key roles in major bio- logical processes, ranging from digestive-protein degra- Key words: genomic analysis; hyperthermophile; clon- dation, as effected by carboxypeptidase A and B,7,8) to ing; expression; carboxypeptidase specific proteolytic processing, as in the maturation of biologically active peptides, as effected by carboxypep- Carboxypeptidases (CPs) act at C-terminals of the tidase N and enkephalin convertase.9,10) It has been polypeptide chain and liberate a single amino acid. They suggested that the broad specificities of P. furiosus CP can be divided into three major groups, serine carboxy- against synthetic and natural peptide substrates might peptidases, metallocarboxypeptidases, and cysteine car- play a role in digestion and protein turnover as opposed boxypeptidases, based on the nature of the amino acid to specific post-translational modification as seen in residues at the active site of the enzymes. higher organisms.4) Metallocarboxyproteases are characterized by the There is growing interest in thermostable enzymes requirement of a divalent metal ion for their activity. because of their broad range of biotechnological Thermostable carboxypeptidase 1 (EC 3.4.17.19), be- applications and as useful models to understand better longing to peptidase family M32, is distinct from other the structural basis of thermostability.11,12) The broad metallocarboxypeptidases, since it contains a HEXXH substrate specificities of thermostable carboxypeptidase metal-binding motif.1) Several thermostable carboxy- 1 allow their use in C-terminal sequencing of pro- peptidase 1 genes that span all three kingdoms of life, teins.2,4) Using N-acetyl-renin substrate, P. furiosus CP namely archaea, bacteria, and eucarya, have been was able to sequence up to seven residues from the C- identified. Among them, the only three thermostable terminus releasing Leu, Val, Phe, Tyr, Ser, and His carboxypeptidase 1 from Thermus aquaticus (carboxy- residues. y To whom correspondence should be addressed. Tel: +82-31-400-6243; Fax: +82-31-406-2495; E-mail: [email protected] Characterization of an Archaeal Carboxypeptidase 1141 Recently, we isolated a hyperthermophilic archaeon, 1 h at 4 C). To purify TNA1 CP with the His6-Tag, Thermococcus sp. NA1, and the whole genome se- the resulting supernatant was applied to a column of quence was determined in order to search for valuable, TALONÔ metal affinity resin (BD Biosciences Clon- extremely thermostable enzymes. Analysis of the ge- tech, Palo Alto, CA) and washed with 10 mM imidazole nome information of Thermococcus sp. NA1 showed a (Sigma, St. Louis, MO) in 50 mM Tris–HCl buffer (pH carboxypeptidase gene belonging to thermostable car- 8.0) containing 0.1 M KCl and 10% glycerol, TNA1 CP boxypeptidase 1. In this study, we describe the cloning was eluted with 300 mM imidazole in the buffer. To of the gene and characterization of the recombinant purify TNA1 CP (no tag), the supernatant was applied to enzyme with regard to its enzymatic properties. a column of HiTrap Q (5 ml, Amersham Biosciences) equilibrated with 50 mM Tris–HCl (pH 7.5). A gradient Materials and Methods from 0 to 1 M KCl in the same buffer was applied to the column. The active fractions were pooled and concen- Strains and growth conditions. E. coli DH5 was trated using Centricon YM-10 (Millipore, Bedford, used for plasmid propagation and nucleotide sequenc- MA). The sample was applied to a Superdex 200 ing. E. coli BL21-CodonPlus(DE3)-RIL cells (Strata- 10/300 GL column (Amersham Biosciences) equili- gene, LaJolla, CA) and plasmid pET-24a(þ) (Novagen, brated with 50 mM Tris–HCl (pH 8.0) and 0.15 M NaCl. Madison, WI) were used for gene expression. E. coli The active fractions of TNA1 CP and TNA1 CP (no tag) strains were cultivated in Luria-Bertani medium at were then buffer exchanged to 50 mM Tris–HCl buffer 37 C, and kanamycin was added to the medium at a (pH 8.0) containing 10% glycerol using Centricon final concentration of 50 mg/ml. YM-10. The protein concentration was estimated from the DNA manipulation and sequencing. DNA manipula- absorbance at 280 nm using an extinction coefficient of À À tions were performed by standard procedures, as 90,750 M 1 cm 1. The protein purity was examined described by Sambrook and Russell.13) Restriction by sodium dodecyl sulfate–polyacrylamide gel electro- enzymes and other modifying enzymes were purchased phoresis (SDS–PAGE) analysis performed according to from Promega (Madison, WI). Small-scale preparation the standard procedure. Gel filtration of the pure enzyme of plasmid DNA from E. coli cells was performed with a was performed on a Superdex 200 10/300 GL column plasmid mini kit (Qiagen, Hilden, Germany). DNA using fast protein liquid chromatography (A¨ kta FPLC sequencing was performed with the automated sequenc- System, Amersham Biosciences), equilibrated with 50 er (ABI3100) using a BigDye terminator kit (PE Applied mM Tris–HCl (pH 8.0) and 0.2 M KCl. Thirty mg protein Biosystems, Foster City, CA). was loaded and eluted at a flow rate of 0.4 ml/min. Cloning and expression of the carboxypeptidase- Enzyme assays. TNA1 CP activity was assayed by encoding gene. Based on the whole genome sequence measuring the hydrolysis of N-Cbz-Alanyl-Arginine (Z- of Thermococcus sp. NA1, the full length of a Ala-Arg) (Bachem AG, Bubendorf, Switzerland). The carboxypeptidase gene (TNA1 CP) flanked by the NdeI assay mixture (250 ml) contained 50 mM KMES (potas- and HindIII sites was amplified by PCR with genomic sium 2-[N-morpholino]ethanesulfonic acid) buffer (pH 0 DNA and three primers (sense [5 -CGACCCGGCAT- 6.5), 0.4 mM CoCl2, and 8 mM substrate. The reaction ATGGAGGAAGTTTTCCAGAACGAAACC-30], anti- was initiated by addition of the enzyme and was sense 1 [50-CTCCACATAAGCTTGAGGTACCTCTCC- incubated at 80 C for 10 min, followed by quenching TTCACCCAGCG-30], and antisense 2 [50-CTCCACA- on ice. Subsequently, 600 ml of cadmium-ninhydrin TAAGCTTTCAGAGGTACCTCTCCTTCACCCAGCG- reagent was added, and the samples were incubated for 30]; the italicized sequences indicate the NdeI site in an additional 5 min at 80 C for color development, the sense primer and the HindIII site in the antisense followed by quenching on ice.14) The absorbance was primers). The amplified DNA fragments were digested read at 500 nm and the enzyme activity was calculated with NdeI and HindIII. The fragments were then ligated using the arginine standard curve. One unit of activity with NdeI/HindIII digested pET-24a(þ), and the result- was defined as the amount of enzyme that liberates ing recombinant plasmids were used to transform E. coli 1 mmol of arginine from Z-Ala-Arg per min at 80 C. DH5 . The recombinant plasmids were introduced Activity assays for other Z-Ala-X amino acid substrates into BL21-CodonPlus(DE3)-RIL for expression after (X = Ala, Asp, His, Leu, Met, Asn, Pro, Val, and Tyr) sequence confirmation. Overexpression was induced were performed under otherwise identical assay con- by the addition of isopropyl- -D-thiogalactopyranoside ditions. Appropriate amino acids were used to prepare (IPTG) at the mid-exponential growth phase and standard curves. incubation for 3 h at 37 C. The cells were harvested by centrifugation (6;000 Â g for 20 min at 4 C) and C-Terminal ladder sequencing of N-acetyl rennin resuspended in 50 mM Tris–HCl buffer (pH 8.0) con- substrate with TNA1 CP.
Recommended publications
  • (12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002
    USOO6395889B1 (12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002 (54) NUCLEIC ACID MOLECULES ENCODING WO WO-98/56804 A1 * 12/1998 ........... CO7H/21/02 HUMAN PROTEASE HOMOLOGS WO WO-99/0785.0 A1 * 2/1999 ... C12N/15/12 WO WO-99/37660 A1 * 7/1999 ........... CO7H/21/04 (75) Inventor: fish E. Robison, Wilmington, MA OTHER PUBLICATIONS Vazquez, F., et al., 1999, “METH-1, a human ortholog of (73) Assignee: Millennium Pharmaceuticals, Inc., ADAMTS-1, and METH-2 are members of a new family of Cambridge, MA (US) proteins with angio-inhibitory activity', The Journal of c: - 0 Biological Chemistry, vol. 274, No. 33, pp. 23349–23357.* (*) Notice: Subject to any disclaimer, the term of this Descriptors of Protease Classes in Prosite and Pfam Data patent is extended or adjusted under 35 bases. U.S.C. 154(b) by 0 days. * cited by examiner (21) Appl. No.: 09/392, 184 Primary Examiner Ponnathapu Achutamurthy (22) Filed: Sep. 9, 1999 ASSistant Examiner William W. Moore (51) Int. Cl." C12N 15/57; C12N 15/12; (74) Attorney, Agent, or Firm-Alston & Bird LLP C12N 9/64; C12N 15/79 (57) ABSTRACT (52) U.S. Cl. .................... 536/23.2; 536/23.5; 435/69.1; 435/252.3; 435/320.1 The invention relates to polynucleotides encoding newly (58) Field of Search ............................... 536,232,235. identified protease homologs. The invention also relates to 435/6, 226, 69.1, 252.3 the proteases. The invention further relates to methods using s s s/ - - -us the protease polypeptides and polynucleotides as a target for (56) References Cited diagnosis and treatment in protease-mediated disorders.
    [Show full text]
  • Enzymatic Encoding Methods for Efficient Synthesis Of
    (19) TZZ__T (11) EP 1 957 644 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 15/10 (2006.01) C12Q 1/68 (2006.01) 01.12.2010 Bulletin 2010/48 C40B 40/06 (2006.01) C40B 50/06 (2006.01) (21) Application number: 06818144.5 (86) International application number: PCT/DK2006/000685 (22) Date of filing: 01.12.2006 (87) International publication number: WO 2007/062664 (07.06.2007 Gazette 2007/23) (54) ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES ENZYMVERMITTELNDE KODIERUNGSMETHODEN FÜR EINE EFFIZIENTE SYNTHESE VON GROSSEN BIBLIOTHEKEN PROCEDES DE CODAGE ENZYMATIQUE DESTINES A LA SYNTHESE EFFICACE DE BIBLIOTHEQUES IMPORTANTES (84) Designated Contracting States: • GOLDBECH, Anne AT BE BG CH CY CZ DE DK EE ES FI FR GB GR DK-2200 Copenhagen N (DK) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • DE LEON, Daen SK TR DK-2300 Copenhagen S (DK) Designated Extension States: • KALDOR, Ditte Kievsmose AL BA HR MK RS DK-2880 Bagsvaerd (DK) • SLØK, Frank Abilgaard (30) Priority: 01.12.2005 DK 200501704 DK-3450 Allerød (DK) 02.12.2005 US 741490 P • HUSEMOEN, Birgitte Nystrup DK-2500 Valby (DK) (43) Date of publication of application: • DOLBERG, Johannes 20.08.2008 Bulletin 2008/34 DK-1674 Copenhagen V (DK) • JENSEN, Kim Birkebæk (73) Proprietor: Nuevolution A/S DK-2610 Rødovre (DK) 2100 Copenhagen 0 (DK) • PETERSEN, Lene DK-2100 Copenhagen Ø (DK) (72) Inventors: • NØRREGAARD-MADSEN, Mads • FRANCH, Thomas DK-3460 Birkerød (DK) DK-3070 Snekkersten (DK) • GODSKESEN,
    [Show full text]
  • Structure of Human Aspartyl Aminopeptidase Complexed With
    Chaikuad et al. BMC Structural Biology 2012, 12:14 http://www.biomedcentral.com/1472-6807/12/14 RESEARCH ARTICLE Open Access Structure of human aspartyl aminopeptidase complexed with substrate analogue: insight into catalytic mechanism, substrate specificity and M18 peptidase family Apirat Chaikuad1, Ewa S Pilka1, Antonio De Riso2, Frank von Delft1, Kathryn L Kavanagh1, Catherine Vénien-Bryan2, Udo Oppermann1,3 and Wyatt W Yue1* Abstract Backround: Aspartyl aminopeptidase (DNPEP), with specificity towards an acidic amino acid at the N-terminus, is the only mammalian member among the poorly understood M18 peptidases. DNPEP has implicated roles in protein and peptide metabolism, as well as the renin-angiotensin system in blood pressure regulation. Despite previous enzyme and substrate characterization, structural details of DNPEP regarding ligand recognition and catalytic mechanism remain to be delineated. Results: The crystal structure of human DNPEP complexed with zinc and a substrate analogue aspartate-β- hydroxamate reveals a dodecameric machinery built by domain-swapped dimers, in agreement with electron microscopy data. A structural comparison with bacterial homologues identifies unifying catalytic features among the poorly understood M18 enzymes. The bound ligands in the active site also reveal the coordination mode of the binuclear zinc centre and a substrate specificity pocket for acidic amino acids. Conclusions: The DNPEP structure provides a molecular framework to understand its catalysis that is mediated by active site loop swapping, a mechanism likely adopted in other M18 and M42 metallopeptidases that form dodecameric complexes as a self-compartmentalization strategy. Small differences in the substrate binding pocket such as shape and positive charges, the latter conferred by a basic lysine residue, further provide the key to distinguishing substrate preference.
    [Show full text]
  • Molecular Markers of Serine Protease Evolution
    The EMBO Journal Vol. 20 No. 12 pp. 3036±3045, 2001 Molecular markers of serine protease evolution Maxwell M.Krem and Enrico Di Cera1 ment and specialization of the catalytic architecture should correspond to signi®cant evolutionary transitions in the Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Box 8231, St Louis, history of protease clans. Evolutionary markers encoun- MO 63110-1093, USA tered in the sequences contributing to the catalytic apparatus would thus give an account of the history of 1Corresponding author e-mail: [email protected] an enzyme family or clan and provide for comparative analysis with other families and clans. Therefore, the use The evolutionary history of serine proteases can be of sequence markers associated with active site structure accounted for by highly conserved amino acids that generates a model for protease evolution with broad form crucial structural and chemical elements of applicability and potential for extension to other classes of the catalytic apparatus. These residues display non- enzymes. random dichotomies in either amino acid choice or The ®rst report of a sequence marker associated with serine codon usage and serve as discrete markers for active site chemistry was the observation that both AGY tracking changes in the active site environment and and TCN codons were used to encode active site serines in supporting structures. These markers categorize a variety of enzyme families (Brenner, 1988). Since serine proteases of the chymotrypsin-like, subtilisin- AGY®TCN interconversion is an uncommon event, it like and a/b-hydrolase fold clans according to phylo- was reasoned that enzymes within the same family genetic lineages, and indicate the relative ages and utilizing different active site codons belonged to different order of appearance of those lineages.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,824 B2 Ramseier Et Al
    USOO8603824B2 (12) United States Patent (10) Patent No.: US 8,603,824 B2 Ramseier et al. (45) Date of Patent: Dec. 10, 2013 (54) PROCESS FOR IMPROVED PROTEIN 5,399,684 A 3, 1995 Davie et al. EXPRESSION BY STRAIN ENGINEERING 5,418, 155 A 5/1995 Cormier et al. 5,441,934 A 8/1995 Krapcho et al. (75) Inventors: Thomas M. Ramseier, Poway, CA 5,508,192 A * 4/1996 Georgiou et al. .......... 435/252.3 (US); Hongfan Jin, San Diego, CA 5,527,883 A 6/1996 Thompson et al. (US); Charles H. Squires, Poway, CA 5,558,862 A 9, 1996 Corbinet al. 5,559,015 A 9/1996 Capage et al. (US) 5,571,694 A 11/1996 Makoff et al. (73) Assignee: Pfenex, Inc., San Diego, CA (US) 5,595,898 A 1/1997 Robinson et al. 5,610,044 A 3, 1997 Lam et al. (*) Notice: Subject to any disclaimer, the term of this 5,621,074 A 4/1997 Bjorn et al. patent is extended or adjusted under 35 5,622,846 A 4/1997 Kiener et al. 5,641,671 A 6/1997 Bos et al. U.S.C. 154(b) by 471 days. 5,641,870 A 6/1997 Rinderknecht et al. 5,643,774 A 7/1997 Ligon et al. (21) Appl. No.: 11/189,375 5,662,898 A 9/1997 Ligon et al. (22) Filed: Jul. 26, 2005 5,677,127 A 10/1997 Hogan et al. 5,683,888 A 1 1/1997 Campbell (65) Prior Publication Data 5,686,282 A 11/1997 Lam et al.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Anti-Inflammatory Role of Curcumin in LPS Treated A549 Cells at Global Proteome Level and on Mycobacterial Infection
    Anti-inflammatory Role of Curcumin in LPS Treated A549 cells at Global Proteome level and on Mycobacterial infection. Suchita Singh1,+, Rakesh Arya2,3,+, Rhishikesh R Bargaje1, Mrinal Kumar Das2,4, Subia Akram2, Hossain Md. Faruquee2,5, Rajendra Kumar Behera3, Ranjan Kumar Nanda2,*, Anurag Agrawal1 1Center of Excellence for Translational Research in Asthma and Lung Disease, CSIR- Institute of Genomics and Integrative Biology, New Delhi, 110025, India. 2Translational Health Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, 110067, India. 3School of Life Sciences, Sambalpur University, Jyoti Vihar, Sambalpur, Orissa, 768019, India. 4Department of Respiratory Sciences, #211, Maurice Shock Building, University of Leicester, LE1 9HN 5Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia- 7003, Bangladesh. +Contributed equally for this work. S-1 70 G1 S 60 G2/M 50 40 30 % of cells 20 10 0 CURI LPSI LPSCUR Figure S1: Effect of curcumin and/or LPS treatment on A549 cell viability A549 cells were treated with curcumin (10 µM) and/or LPS or 1 µg/ml for the indicated times and after fixation were stained with propidium iodide and Annexin V-FITC. The DNA contents were determined by flow cytometry to calculate percentage of cells present in each phase of the cell cycle (G1, S and G2/M) using Flowing analysis software. S-2 Figure S2: Total proteins identified in all the three experiments and their distribution betwee curcumin and/or LPS treated conditions. The proteins showing differential expressions (log2 fold change≥2) in these experiments were presented in the venn diagram and certain number of proteins are common in all three experiments.
    [Show full text]
  • Of Pseudomonas Aeruginosa Cristian Gustavo Aguilera Rossi1,2, Paulino Gómez-Puertas3 and Juan Alfonso Ayala Serrano2*
    Aguilera Rossi et al. BMC Microbiology (2016) 16:234 DOI 10.1186/s12866-016-0853-x RESEARCH ARTICLE Open Access In vivo functional and molecular characterization of the Penicillin-Binding Protein 4 (DacB) of Pseudomonas aeruginosa Cristian Gustavo Aguilera Rossi1,2, Paulino Gómez-Puertas3 and Juan Alfonso Ayala Serrano2* Abstract Background: Community and nosocomial infections by Pseudomonas aeruginosa still create a major therapeutic challenge. The resistance of this opportunist pathogen to β-lactam antibiotics is determined mainly by production of the inactivating enzyme AmpC, a class C cephalosporinase with a regulation system more complex than those found in members of the Enterobacteriaceae family. This regulatory system also participates directly in peptidoglycan turnover and recycling. One of the regulatory mechanisms for AmpC expression, recently identified in clinical isolates, is the inactivation of LMM-PBP4 (Low-Molecular-Mass Penicillin-Binding Protein 4), a protein whose catalytic activity on natural substrates has remained uncharacterized until now. Results: We carried out in vivo activity trials for LMM-PBP4 of Pseudomonas aeruginosa on macromolecular peptidoglycan of Escherichia coli and Pseudomonas aeruginosa. The results showed a decrease in the relative quantity of dimeric, trimeric and anhydrous units, and a smaller reduction in monomer disaccharide pentapeptide (M5) levels, validating the occurrence of D,D-carboxypeptidase and D,D-endopeptidase activities. Under conditions of induction for this protein and cefoxitin treatment, the reduction in M5 is not fully efficient, implying that LMM- PBP4 of Pseudomonas aeruginosa presents better behaviour as a D,D-endopeptidase. Kinetic evaluation of the direct D,D-peptidase activity of this protein on natural muropeptides M5 and D45 confirmed this bifunctionality and the greater affinity of LMM-PBP4 for its dimeric substrate.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110747 A1 Ramseier Et Al
    US 200601 10747A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110747 A1 Ramseier et al. (43) Pub. Date: May 25, 2006 (54) PROCESS FOR IMPROVED PROTEIN (60) Provisional application No. 60/591489, filed on Jul. EXPRESSION BY STRAIN ENGINEERING 26, 2004. (75) Inventors: Thomas M. Ramseier, Poway, CA Publication Classification (US); Hongfan Jin, San Diego, CA (51) Int. Cl. (US); Charles H. Squires, Poway, CA CI2O I/68 (2006.01) (US) GOIN 33/53 (2006.01) CI2N 15/74 (2006.01) Correspondence Address: (52) U.S. Cl. ................................ 435/6: 435/7.1; 435/471 KING & SPALDING LLP 118O PEACHTREE STREET (57) ABSTRACT ATLANTA, GA 30309 (US) This invention is a process for improving the production levels of recombinant proteins or peptides or improving the (73) Assignee: Dow Global Technologies Inc., Midland, level of active recombinant proteins or peptides expressed in MI (US) host cells. The invention is a process of comparing two genetic profiles of a cell that expresses a recombinant (21) Appl. No.: 11/189,375 protein and modifying the cell to change the expression of a gene product that is upregulated in response to the recom (22) Filed: Jul. 26, 2005 binant protein expression. The process can improve protein production or can improve protein quality, for example, by Related U.S. Application Data increasing solubility of a recombinant protein. Patent Application Publication May 25, 2006 Sheet 1 of 15 US 2006/0110747 A1 Figure 1 09 010909070£020\,0 10°0 Patent Application Publication May 25, 2006 Sheet 2 of 15 US 2006/0110747 A1 Figure 2 Ester sers Custer || || || || || HH-I-H 1 H4 s a cisiers TT closers | | | | | | Ya S T RXFO 1961.
    [Show full text]
  • 1 No. Affymetrix ID Gene Symbol Genedescription Gotermsbp Q Value 1. 209351 at KRT14 Keratin 14 Structural Constituent of Cyto
    1 Affymetrix Gene Q No. GeneDescription GOTermsBP ID Symbol value structural constituent of cytoskeleton, intermediate 1. 209351_at KRT14 keratin 14 filament, epidermis development <0.01 biological process unknown, S100 calcium binding calcium ion binding, cellular 2. 204268_at S100A2 protein A2 component unknown <0.01 regulation of progression through cell cycle, extracellular space, cytoplasm, cell proliferation, protein kinase C inhibitor activity, protein domain specific 3. 33323_r_at SFN stratifin/14-3-3σ binding <0.01 regulation of progression through cell cycle, extracellular space, cytoplasm, cell proliferation, protein kinase C inhibitor activity, protein domain specific 4. 33322_i_at SFN stratifin/14-3-3σ binding <0.01 structural constituent of cytoskeleton, intermediate 5. 201820_at KRT5 keratin 5 filament, epidermis development <0.01 structural constituent of cytoskeleton, intermediate 6. 209125_at KRT6A keratin 6A filament, ectoderm development <0.01 regulation of progression through cell cycle, extracellular space, cytoplasm, cell proliferation, protein kinase C inhibitor activity, protein domain specific 7. 209260_at SFN stratifin/14-3-3σ binding <0.01 structural constituent of cytoskeleton, intermediate 8. 213680_at KRT6B keratin 6B filament, ectoderm development <0.01 receptor activity, cytosol, integral to plasma membrane, cell surface receptor linked signal transduction, sensory perception, tumor-associated calcium visual perception, cell 9. 202286_s_at TACSTD2 signal transducer 2 proliferation, membrane <0.01 structural constituent of cytoskeleton, cytoskeleton, intermediate filament, cell-cell adherens junction, epidermis 10. 200606_at DSP desmoplakin development <0.01 lectin, galactoside- sugar binding, extracellular binding, soluble, 7 space, nucleus, apoptosis, 11. 206400_at LGALS7 (galectin 7) heterophilic cell adhesion <0.01 2 S100 calcium binding calcium ion binding, epidermis 12. 205916_at S100A7 protein A7 (psoriasin 1) development <0.01 S100 calcium binding protein A8 (calgranulin calcium ion binding, extracellular 13.
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]